Back to search

The University of Edinburgh

Investigation of novel theranostic antimicrobial photodynamic therapy agents

Abstract

dc:description.abstract

Background With increasing rates of antimicrobial resistances across the world, as well as other limitations of current antibiotic measures such as lack of specific targets, ineffectiveness in various environments such as biofilms, and cytotoxicity, targeted antimicrobial photodynamic therapy (aPDT) offers a novel alternative to traditional antimicrobial treatment. PDT involves light activation of photosensitisers (PS) to produce singlet oxygen and reactive oxygen species (ROS) which generates localised oxidative killing of the cells it is bound to. Due to common issues of commercial PS used in conventional PDT (e.g. against tumours), including the lack of specificity leading to high off-target cytotoxicity, and requiring high dosage for efficacy, novel pathogen-specific aPDT compounds were developed. VanB2 and SeNBD-Van were synthesised to target and kill Gram-positive pathogens, whereby SeONBD-UBI was synthesised to target all pathogens, including fungi. Further properties of the novel aPDT PS were to include fluorophore components for fluorescent imaging of the pathogens, thus enabling pathogen detection prior to the targeted killing. Finally, to address issues of drug delivery, specifically in the treatments for microbial keratitis (infection of the cornea), a novel drug delivery utilising cornea bandages was validated and tested in combination with the delivery of aPDT agents to maximise bacterial killing efficacy in microbial keratitis wound clearing. Aims 1. To evaluate and measure efficacy of the three novel aPDT PS against a panel of Gram-positive and Gram-negative bacteria, with a multitude of antibiotic resistances/susceptibility profiles, and under different growth conditions, including planktonic, biofilm and ex vivo infection models. 2. To measure the level of off-target cellular cytotoxicity against relevant mammalian cells. 3. To characterise and optimise the usage of novel hydrogel cornea bandages in the delivery of aPDT agents in microbial keratitis wound clearing. Methods Three novel aPDT photosensitisers (VanB2, SeNBD-Van and SeONBD-UBI) were tested against a panel of antimicrobial sensitive and resistant bacteria and fungi grown in liquid media, solid media biofilms and in-vitro porcine models (skin and cornea infections). Target binding was confirmed by confocal scanning laser microscopy (CLSM). aPDT activity was activated by LED illumination (VanB2 was illuminated at 450nm, ~ 30 mW/cm2 ; SeNBD-Van and SeONBD-UBI were illuminated at 470nm, ~45 mW/cm2 ). Post treatment, bacteria samples were plated to identify effect via colony forming units (CFUs). Off target effects were measured against mammalian cells (human erythrocytes and HaCaT keratinocyte line). Haemolysis and WST-1 cell viability assays were used to determine cellular viability of mammalian cells after exposure to aPDT agents. Results VanB2 demonstrated effective binding and activity specifically against Gram-positive bacteria, including those with antimicrobial resistance. It was able to cause a complete 100% reduction (up to the limit of detection of experiments) of bacteria load (~107 log10 reduction). It remained effective against the biofilm infection model. It was also effective at low concentrations (eradication of S. aureus even at 0.63 µM) as well as low light intensities (2 min of illumination eradicated of S. aureus). It caused minimal cytotoxicity against the mammalian cells tested. SeNBD-Van also demonstrated high rapid efficacy in light mediated oxidative killing against Gram-positive bacteria, with the added benefit of target-binding confirmation by fluorescence microscopy. This remained highly effective against multidrug resistance bacteria, including vancomycin resistant Enterococcus faecalis (VRE), as well as in ex-vivo porcine skin and cornea models and in-vitro biofilms. When tested against mammalian cells in haemolysis assays and WST-1 assays, the probe demonstrated limited toxicity against mammalian cells. SeONBD-UBI was designed to bind to both Gram-positive and Gram-negative bacteria, as well as fungi. It successfully demonstrated good killing efficacy against various panels of multi-drug resistant ESKAPE bacteria, commonly associated with persistent hospital acquired infections. CLSM imaging also demonstrated selective binding to bacteria. They also demonstrated capacity for bacterial clearing in various biofilm and porcine skin and cornea infection models. In the investigation of the effectiveness of novel cornea bandages as an alternative to liquid formulation drug delivery, aPDT agents SeNBD-Van and SeONBD-UBI were incorporated into the gels and cumulative drug release over time was recorded via absorbance. Loaded gels were then tested against bacteria both on solid and in liquid media, demonstrating drug release and subsequent aPDT action, even exhibiting 100% reduction of S. aureus in liquid media. This was finally incorporated into the existing oxygen biofilm and cornea infection models demonstrating varying success. Conclusion Novel aPDT photosensitisers, designed for specific targeting of pathogens for rapid detection and oxidative killing, allow for effective elimination of targeted pathogens, including those with existing antimicrobial resistances. VanB2, SeNBD-Van and SeONBD-UBI achieved high levels of success as aPDT and imaging agents against bacteria and fungi, with minimal off-target cytotoxicity. Therefore, these novel aPDT agents overcome the common limitations of currently available PS used within the clinic, and offer a promising alternative to antimicrobials, particularly for the treatment of antimicrobial resistant infections.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kiang, Alex
Advisors dc:contributor.advisor
  • Mills, Bethany
  • Dhaliwal, Kanwaldeep

Subjects

dc:subject × 7

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kiang, Alex. Investigation of novel theranostic antimicrobial photodynamic therapy agents. The University of Edinburgh, 2025. https://hdl.handle.net/1842/43501